Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
119
Recruiting, any sponsor type, condition "Crohn"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting119
- Completed435
119 trials
Showing 1 to 25, recently updated first.
- A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07184944 · 751 participants (planned) · Start Jan 22, 2026 · Primary completion Aug 13, 2029
Drug: Duvakitug; Placebo · For: Crohn's Disease
Sites: Colorado Springs, Colorado; Clermont, Florida; Kissimmee, Florida · 152 sites in all
- Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's DiseasePivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT06548542 · 590 participants (planned) · Start Sep 4, 2024 · Primary completion Jan 2030
Drug: Risankizumab; Lutikizumab and 4 more · For: Crohn's Disease
Sites: Dothan, Alabama; Mobile, Alabama; Coronado, California · 255 sites in all
- An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07184931 · 980 participants (planned) · Start Oct 1, 2025 · Primary completion May 14, 2029
Drug: Duvakitug; Placebo · For: Crohn's Disease
Sites: Peoria, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 481 sites in all
- Modafinil For Fatigue in IBDRecruiting
Imperial College LondonAcademic, hospital or other
NCT07295834 · 70 participants (planned) · Start May 5, 2026 · Primary completion Dec 1, 2027
Drug: Modafinil; Placebo · For: Crohn Disease (CD); Ulcerative Colitis (UC); Fatigue
Sites: London, United Kingdom · 4 sites in all
- A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's DiseaseRecruiting
SanofiSanofi (SNY)
NCT06958536 · 99 participants (planned) · Start Jun 3, 2025 · Primary completion Dec 17, 2026
Drug: brivekimig; Placebo · For: Crohn's Disease
Sites: Fairhope, Alabama; Tucson, Arizona; Escondido, California · 78 sites in all
- Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's DiseaseRecruiting
Madeleine BezaultAcademic, hospital or other
NCT06925061 · 80 participants (planned) · Start Mar 31, 2025 · Primary completion Dec 31, 2026
Drug: After surgery for Crohn's disease, eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment (based on investigator decision) for up to 24 weeks · For: Crohn Disease (CD)
Sites: Clermont-Ferrand, France; Créteil, France; Le Kremlin-Bicêtre, France · 12 sites in all
National Cancer Institute (NCI)NIH
NCT03816345 · 300 participants (planned) · Start Jul 16, 2019 · Primary completion Mar 30, 2028
Drug: Cabozantinib; Fluoropyrimidine and 4 more · For: Autoimmune Disease; Crohn Disease; Dermatomyositis and 11 more
Sites: Birmingham, Alabama; Palo Alto, California; Sacramento, California · 52 sites in all
TakedaTakeda (TAK)
NCT06581328 · 200 participants (planned) · Start Mar 27, 2025 · Primary completion May 1, 2027
Drug: Vedolizumab IV; Vedolizumab SC · For: Ulcerative Colitis; Crohn's Disease
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 101 sites in all
- A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)Pivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT06405087 · 70 participants (planned) · Start Oct 27, 2025 · Primary completion Aug 12, 2030
Drug: Vedolizumab SC · For: Ulcerative Colitis; Crohn's Disease
Sites: Phoenix, Arizona; Loma Linda, California; Orange, California · 45 sites in all
- A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06430801 · 1,200 participants (planned) · Start Jun 5, 2024 · Primary completion Oct 30, 2028
Drug: IV Tulisokibart; SC Tulisokibart · For: Crohn's Disease
Sites: Dothan, Alabama; Phoenix, Arizona; Sun City, Arizona · 499 sites in all
- A Study of SL-325 in Crohn's Disease PatientsPivotal-lookingRecruiting
Shattuck Labs, Inc.Industry
NCT07753850 · 232 participants (planned) · Start Nov 9, 2026 · Primary completion Jul 2028
Drug: SL-325; Placebo · For: Crohn's Disease
Sites: Little Rock, Arkansas; Oxnard, California; Temple City, California · 20 sites in all
TakedaTakeda (TAK)
NCT05113095 · 275 participants (planned) · Start Nov 30, 2021 · Primary completion Dec 31, 2029
Drug: Darvadstrocel · For: Crohn's Disease
Sites: Tokyo, Japan
Pontificia Universidad Catolica de ChileAcademic, hospital or other
NCT06758024 · 72 participants (planned) · Start Jan 24, 2025 · Primary completion Mar 2027
Drug: Infliximab; Infliximab · For: Inflammatory Bowel Disease (IBD); Crohn Disease (CD); Ulcerative Colitis (UC)
Sites: Santiago, Chile
- Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06651281 · 1,380 participants (planned) · Start Nov 25, 2024 · Primary completion Dec 17, 2037
Drug: Tulisokibart; Placebo to tulisokibart · For: Crohn Disease; Colitis, Ulcerative
Sites: Bristol, Connecticut; Ypsilanti, Michigan; Liberty, Missouri · 37 sites in all
- Iron Treatment for Iron Deficiency Anemia in Children and Young Adults With Crohn's DiseasePivotal-lookingRecruiting
Weill Medical College of Cornell UniversityAcademic, hospital or other
NCT07925450 · 150 participants (planned) · Start Sep 13, 2023 · Primary completion Mar 13, 2029
Drug: Iron (ferrous sulfate) · For: Crohn's Disease; Iron Deficiency Anemia
Sites: New York, New York
Eli Lilly and CompanyEli Lilly (LLY)
NCT07483073 · 60 participants (planned) · Start May 4, 2026 · Primary completion Jun 2027
Drug: Mirikizumab - Intravenous (IV); Mirikizumab - Subcutaneous (SC) and 1 more · For: Colitis, Ulcerative; Crohn Disease
Sites: Scottsdale, Arizona; Los Angeles, California; Oxnard, California · 71 sites in all
- Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06937099 · 290 participants (planned) · Start Jun 26, 2025 · Primary completion May 2028
Drug: Mirikizumab; Mirikizumab and 2 more · For: Crohn's Disease; Obesity or Overweight
Sites: Dothan, Alabama; Anaheim, California; Beverly Hills, California · 183 sites in all
- A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)Industry
NCT06226883 · 385 participants (planned) · Start Jul 18, 2024 · Primary completion Sep 2028
Drug: Placebo; MORF-057 · For: Inflammatory Bowel Diseases; Crohn's Disease
Sites: Lancaster, California; San Diego, California; Colorado Springs, Colorado · 224 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07483099 · 60 participants (planned) · Start May 4, 2026 · Primary completion Jun 2027
Drug: LY4395089; Mirikizumab - Intravenous (IV) and 1 more · For: Crohn Disease
Sites: Scottsdale, Arizona; Los Angeles, California; Oxnard, California · 71 sites in all
Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesAcademic, hospital or other
NCT07292012 · 75 participants (planned) · Start May 11, 2026 · Primary completion Nov 2027
Drug: Mirikizumab - IV; Mirikizumab - SC · For: Crohn Disease (CD)
Sites: Brest, France; Caen, France; Clermont-Ferrand, France · 8 sites in all
- A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07499232 · 530 participants (planned) · Start Apr 21, 2026 · Primary completion Nov 15, 2028
Drug: Guselkumab; Risankizumab · For: Crohn Disease
Sites: Dothan, Alabama; Mobile, Alabama; Anaheim, California · 164 sites in all
- A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)Recruiting
Xian-Janssen Pharmaceutical Ltd.Industry
NCT07310095 · 78 participants (planned) · Start Dec 30, 2025 · Primary completion Sep 15, 2027
Drug: Guselkumab (GUS) · For: Crohn Disease
Sites: Guangzhou, China; Hangzhou, China; Hefei, China · 5 sites in all
- A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05923073 · 120 participants (planned) · Start Mar 13, 2024 · Primary completion Oct 27, 2027
Drug: Guselkumab; Guselkumab · For: Crohn's Disease
Sites: Los Angeles, California; Hartford, Connecticut; Atlanta, Georgia · 85 sites in all
- A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07196722 · 1,092 participants (planned) · Start Oct 3, 2025 · Primary completion Sep 19, 2028
Drug: Icotrokinra; Placebo · For: Crohn Disease
Sites: Chandler, Arizona; Litchfield Park, Arizona; Scottsdale, Arizona · 395 sites in all
- A Long-term Extension (LTE) Study of Guselkumab in Pediatric ParticipantsPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06663332 · 196 participants (planned) · Start Oct 29, 2024 · Primary completion Dec 12, 2031
Drug: Guselkumab · For: Crohns Disease; Colitis, Ulcerative; Arthritis, Psoriatic and 1 more
Sites: Atlanta, Georgia; Indianapolis, Indiana; Cincinnati, Ohio · 53 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.